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Prebiotic, probiotic and synbiotic supplementation in chronic kidney disease: a systematic 
review and meta-analysis 
 
Objective 
Gut dysbiosis has been implicated in the pathogenesis of chronic kidney disease (CKD). 
Restoring gut microbiota with prebiotic, probiotic and synbiotic supplementation has 
emerged as a potential therapeutic intervention, but has not been systematically evaluated 
in the CKD population.  
 
Design 
Systematic review 
 
Method 
A structured search of Medline, CINAHL, EMBASE, Cochrane Central Register of Controlled 
Trials and the International Clinical Trials Register Search Portal was conducted for articles 
published since inception until July 2017. Included studies were randomised controlled trials 
investigating the effects of pre-, pro- and/or synbiotic supplementation (>1 week) on 
uraemic toxins, microbiota profile, clinical and patient-centred outcomes in adults and 
children with CKD.  
 
Results 
Sixteen studies investigating 645 adults met the inclusion criteria; five investigated 
prebiotics, six probiotics and five synbiotics. The quality of the studies (GRADE) ranged from 
moderate to very low. Pre-, pro- and synbiotic supplementation may have led to little or no 
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difference in serum urea (9 studies, 345 participants: MD -0.30mmol/L, 95%CI -2.20 to 1.61, 
P=0.76, I2=53%), indoxyl sulphate (4 studies, 144 participants: MD -0.02mg/dL, 95%CI -0.09 
to 0.05, P=0.61, I2=0%) and p-cresyl sulphate (4 studies, 144 participants: MD -0.13mg/dL, 
95% CI -0.41 to 0.15, P=0.35, I2=0%). Prebiotic supplementation may have slightly reduced 
serum urea concentration (4 studies, 105 participants: MD -2.23mmol/L, 95%CI -3.83 to -
0.64, P=0.006, I2=11). Of the two studies investigating microbiota changes, synbiotic 
interventions significantly increased Bifidobacterium. Supplement effects on clinical 
outcomes were uncertain. 
 
Conclusions:  
There is limited evidence to support the use of pre- pro- and/or synbiotics in CKD 
management.  
 
Key words (5): Chronic Kidney Disease, Gut dysbiosis, Prebiotic, Probiotic, Synbiotic, 
Microbiota 
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Introduction  
Chronic kidney disease (CKD) is a major health burden worldwide. (1) The prevalence of CKD 
is steadily increasing (2) and individuals with CKD have a significantly increased risk of 
cardiovascular disease (CVD) (3), which is only partially explained by the traditional risk 
factors of older age, obesity, tobacco use, diabetes mellitus, hypertension and 
dyslipidaemia. (4)  
 
Over the last decade, there has been a growing body of evidence linking gut dysbiosis and 
intestinal wall permeability to progressive kidney failure and cardiovascular risk (5, 6) via 
systemic inflammation and production of uraemic toxins, including indoxyl sulphate (IS), p-
cresyl sulphate (PCS) and trimethylamine N-oxide (TMAO). (7-9) The imbalance of gut micro-
organisms in patients with CKD may be therapeutically modifiable. For example, pre-, pro- 
and synbiotics may competitively decrease the relative population of protein-fermenting 
intestinal flora and consequently reduce the production of uraemic toxins. This is achieved 
by altering the carbohydrate-to-protein ratio and augmenting short-chain fatty-acid 
production.   This low-cost therapy therefore represents an appealing therapeutic strategy. 
 
To date, the results from individual studies investigating the effects of pre-, pro- and/or 
synbiotic supplementation within the CKD population have produced conflicting results. (10-
12) Furthermore, there has been no prior systematic review of the effects of pre-, pro- 
and/or synbiotic supplementation on kidney function, uraemic toxin production, microbiota 
composition and patient-level outcomes exclusively within the CKD population. Therefore, 
the aim of this review was to systematically evaluate randomised controlled trials assessing 
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the effectiveness of pre-, pro- and/or synbiotic supplementation on clinical and patient-
centred outcomes in CKD.  
 
Materials and Methods  
This review was conducted according to PRISMA reporting guidelines following a pre-
specified protocol (PROSPERO CRD42017075771) (13). 
 
Criteria for considering studies 
Studies were included in the review if they met all of the following criteria: 1) randomised 
controlled trial (RCT) including crossover, cluster or quasi-RCT designs; 2) in participants 
with CKD as defined by the Kidney Disease Outcome Quality Initiative (K/DOQI) Guidelines 
(14); and, 3) interventions that included supplementation with pre-, pro- or synbiotics for a 
duration of at least one week. Studies were excluded if they were utilising high dose 
prebiotics for purgation, populations with altered gastrointestinal function and those where 
nutrition was provided enterally. 
 
The primary outcome was change in kidney function (eGFR, serum creatinine) and kidney 
damage (proteinuria, albuminuria). Secondary outcomes included uraemic toxins (urea, free 
and protein bound concentrations of serum indoxyl sulphate [IS] and p-cresyl sulphate 
[PCS], trimethylamine N-oxide [TMAO] phenylacetylglutamine [PAG]), microbiota 
composition, change in clinical markers (fasting blood glucose, HbA1c, weight, waist 
circumference), markers of cardiovascular risk (left ventricular mass index, diastolic 
function, blood pressure, blood lipid profile), infections including antibiotic use, clinical 
outcomes (hospitalisations, cardiovascular events, progression to end-stage kidney disease 
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[ESKD], mortality, adverse events) and patient centred outcomes (colonic transit time, 
faecal characteristics, gastrointestinal tolerance, health related quality of life and treatment 
adherence).  
 
Search methods 
A comprehensive search was conducted using MEDLINE, CINAHL, Embase and Cochrane 
from inception until 2017 utilising a combination of MeSH and free text terms relevant to 
the review in consultation with an experienced systematic review search librarian. MESH 
search terms are outlined in the pre-specified protocol (PROSPERO CRD42017075771). 
Searches of the International Clinical Trials Register and clinicaltrials.gov were undertaken 
to identify any ongoing trials. Additionally, manual searches were performed to retrieve 
relevant studies through citation searches of conference abstracts, theses and biographies 
of relevant published articles. 
 
Data Collection 
Articles were screened independently by two review authors (CM, CIR), with disagreements 
resolved by consensus or discussion with a third reviewer (KLC). Data extraction from 
included studies comprised of intervention details, study design, duration, sample size, 
attrition and participant characteristics. Mean, standard deviations (SD), standard error (SE) 
or 95% confidence intervals (CI) for all pre-specified primary and secondary outcome data 
that were reported at baseline and follow-up were extracted for data analysis. The units of 
measurement for uraemic toxins were converted to mg/dL using molecular weights from 
the Human Metabolome Database. (15) Corresponding authors were contacted for 
information that was not published, including missing numerical data of outcome measures.  
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Assessment of Study and Evidence Quality 
Risk of bias was assessed by two review authors (CM, CR) independently using Cochrane 
methodology (16) The Grades of Recommendation, Assessment, Development and 
Evaluation (GRADE) approach for grading the evidence was applied for each outcome 
category (17) and assessed independently by two review authors (CM, CR). Disagreements 
in risk of bias and GRADE classification were managed by consensus and discussion with a 
third reviewer (KC).  
 
Statistical Analysis 
The overall treatment effects for primary and secondary outcomes were calculated as the 
differences between the intervention and comparison groups’ change scores from baseline 
to the end of follow-up. If the change from baseline score was not available, the end of 
intervention value was extracted with the assumption that no significant differences were 
observed at baseline between intervention and comparison groups.  
 
Quantitative analysis was undertaken for adequately reported outcomes by pooling data 
into Revman (Review Manager 5, version 5.3, The Cochrane Collaboration) for meta-analysis 
through DerSimonian-Laird random-effects model. (16) Heterogeneity between studies was 
assessed using the I2 statistic and was considered substantial if the I2 statistic was ≥50%. 
Publication bias was investigated using funnel plots and Egger’s test. 
 
Results  
Characteristics of Included Studies 
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The search identified 586 citations after removal of duplicates (Figure 1). Sixteen studies 
were included in the review, with a total sample size of 645 participants (individual studies 
ranging from nine to 124 participants) and intervention durations ranging from two to 24 
weeks. All included studies involved adult participants with chronic kidney disease (CKD) 
with seven studies involving non-dialysis patients (7, 9, 18-23), eight studies involving 
patients undergoing haemodialysis for ESKD (8, 24-29) and one study involving participants 
undergoing peritoneal dialysis (30). Five trialled prebiotics (7, 8, 18, 23, 29), six trialled 
probiotics (21, 22, 24, 26, 27, 30) and five trialled synbiotics (9, 19, 20, 25, 28). (Table 1) Pre-
, pro- and synbiotic formulations are outlined in Table 1. Additional information was 
provided by three of the nine contacted authors. (7, 9, 19) 
 
Risk of Bias 
Risk of bias was low in the following domains; detection bias (13 studies) (7-9, 18-22, 24-26, 
28, 30), attrition bias (9 studies) (7, 9, 18, 20, 21, 23, 26-28), performance bias (7 studies) (7, 
9, 19, 20, 24, 28, 30), selection bias (random sequence generation (5 studies) (8, 9, 20, 27, 
30), allocation concealment (6 studies) (7, 9, 20, 24, 27, 30)), and reporting bias (4 studies) 
(7-9, 27). Five studies were rated as having a high risk of attrition bias (through high loss to 
follow-up and no explanation of how data were addressed) (8, 22, 24, 29, 30), four studies 
were rated as having a high risk of performance bias (no blinding or blinding may have been 
broken) (8, 18, 23, 29), while three were rated as having a high risk of reporting bias (a 
number of outcome measures were not reported in the results) (21, 22, 26). Bias related to 
control of dietary intake was low in four studies (9, 23, 28, 29), while four studies were 
rated as having an unclear risk of bias related to dietary advice and assessment of dietary 
compliance (7, 18, 27, 30). The eight studies which did not provide dietary advice nor assess 
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dietary intake were rated as having a high risk of bias related to potential dietary 
confounders. (8, 19-22, 24-26) Three studies were determined as having other risks of bias 
relating to the absence of a wash-out period in crossover trials and possible or undeclared 
conflicts of interest. (18, 21, 22) (Figure 4)  
 
Change in kidney function and damage 
Nutrition supplementation probably made little or no difference to kidney function, 
measured by eGFR (3 studies, 132 participants: MD 0.34mL/min/1.73m2, 95%CI -2.20 to 
2.89, P=0.79, I2=0%; moderate certainty evidence) (Supplementary Figure 1). (7, 9, 19) Two 
studies reported that nutrition supplementation had no impact on serum creatinine (sCr). 
(18, 19) 
 
Kidney damage was reported in one study, with a significant increase in albuminuria 
(38mg/24hr, 95% CI, 1 to 295mg/24hr, P=0.03) noted after synbiotic therapy. (9) The effect 
of nutrition supplementation on proteinuria was not reported as an outcome measure in 
any included study. 
 
Uraemic toxins 
Nutrition supplementation may have led to little or no difference to serum urea (9 studies, 
345 participants: MD -0.30mmol/L, 95%CI -2.20 to 1.61, P=0.76, I2=53%; low certainty 
evidence) (7, 8, 18, 19, 23, 24, 27, 28, 30) (Supplementary Figure 2), serum IS (4 studies, 144 
participants: MD -0.02mg/dL, 95%CI -0.09 to 0.05, P=0.61, I2=0%; moderate certainty 
evidence) (7-9, 24) and serum PCS (4 studies, 144 participants: MD -0.13mg/dL, 95% CI -0.41 
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to 0.15, P=0.35, I2=0%; moderate certainty evidence) (7-9, 24) (Supplementary Figures 3 and 
4).  
 
Sensitivity analyses were conducted to determine the effects that the type of nutrition 
supplementation, CKD stage and duration of intervention had on serum urea levels. 
Prebiotics may have slightly reduced serum urea concentrations (4 studies, 105 participants: 
MD -2.23mmol/L, 95%CI -3.83 to -0.64, P=0.006, I2=11%) (7, 8, 18, 23) though not probiotics 
(3 studies, 132 participants: MD 2.30mmol/L, 95%CI -0.25 to 4.85, P=0.08, I2=0%) (24, 27, 
30) nor synbiotics (2 studies, 108 participants, MD 0.62mmol/L, 95%CI -2.70 to 3.95, P=0.71, 
I2=9%) (19, 28) (Figure 2). A small but statistically significant reduction was observed in 
serum urea concentration in non-dialysis patients (4 studies, 131 participants: MD -
2.12mmol/L, 95%CI -3.86 to -0.37, P=0.02, I2=17%) (7, 18, 19, 23) but not in dialysis patients 
(5 studies, 214 participants: MD 1.36mmol/L, 95%CI -0.76 to 3.48, P=0.21, I2=14%) (8, 24, 
27, 28, 30) (Figure 3). There was no subgroup difference by intervention duration.  
 
Sensitivity analyses demonstrated no subgroup differences by type of nutrition 
supplementation, CKD stage or intervention duration for both IS and PCS.   
 
One study reported the impact of nutrition supplementation on serum TMAO 
concentrations and found prebiotic supplementation resulted in a significant decrease in 
TMAO (-0.237µmol/L, P=0.04). (7) 
 
The impact of nutrition supplementation on serum PAG was reported in one study. (7) 
Prebiotic supplementation had no significant effect on serum PAG (0.080µmol/L P=0.41).  
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Microbiota composition 
Two studies investigated the effect of nutrition supplementation on microbiota 
composition, both were synbiotic studies. (9, 25) Intervention duration ranged from six to 
eight weeks, with 18 to 31 participants. Synbiotic formulation differed between the two 
studies (Table 1). Both studies noted significant increases in Bifidobacterium (3.2% P=0.003 
(9) and 4.2 ± 0.88 log10 cells/g to 5.5 ± 1.72 log10 cells/g P=0.034 (25)) with one study also 
finding a significant increase in Lachnospiraceae (2.1% P=0.01), a non-significant increase in 
Lactobacillus (0.7% P=0.36) and a significant decrease in Ruminococcaceae (4.3% P=0.01). 
(9)  
 
Clinical markers 
Few studies reported on change in clinical markers with pre-, pro- and/or synbiotic 
supplementation. Blood glucose levels were reported in two studies  (7, 27) and weight in 
seven studies (7, 18, 19, 23, 27-29), while waist circumference was not reported in any 
included studies. It was uncertain whether pre- or probiotic supplementation improved 
blood glucose levels as the certainty of this evidence was very low (2 studies, 100 
participants: MD -8.19md/dL, 95%CI -32.45 to 16.07, P=0.51, I2=80%) (7, 27) (Supplementary 
Figure 5). Heterogeneity was not able to be explained through sensitivity analyses. 
Compared to placebo, pre-, pro- and/or synbiotic supplementation may have had little or no 
impact on weight (7 studies, 357 participants: MD 0.40kg, 95%CI -0.95 to 1.74, P=0.56, 
I2=0%; low certainty evidence) (7, 18, 19, 23, 27-29) (Supplementary Figure 6). 
 
Cardiovascular risk 
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Few studies reported on the effect of pre-, pro- and/or synbiotic supplementation on 
cardiovascular risk. Blood lipids were reported in three studies. (27-29) It was uncertain 
whether nutrition supplementation improved total cholesterol (3 studies, 226 participants: 
MD -6.23mg/dL, 95%CI -25.86 to 13.41, P=0.53, I2=76%), LDL cholesterol (3 studies, 226 
participants: MD -5.50mg/dL, 95%CI -15.54 to 4.54, P=0.28, I2=83%) or triglyceride levels (3 
studies, 226 participants: MD -1.57mg/dL, 95%CI -22.56 to 19.42, P=0.88, I2=0%) as the 
certainty of this evidence was very low. (Supplementary Figures 7, 8 and 9) Heterogeneity 
was not able to be explained through sensitivity analyses. Left ventricular mass index, 
diastolic function and blood pressure were not reported in any included studies. 
 
Infections 
None of the included studies reported an infection as an adverse event. One study reported 
on antibiotic use throughout the intervention. (9) Patients who did not receive antibiotics 
during the study had marked reductions in IS (-5µmol/L, 95%CI -8 to -1µmol/L, P=0.03) and 
PCS (-25µmol/L, 95%CI -38 to -12µmol/L, P=0.001) compared to those who received 
antibiotics. Antibiotic use preceding baseline visit was an exclusion criterion in six of the 16 
studies. (7-9, 19, 27, 30)   
 
Adverse events 
Three studies provided data on adverse events. (9, 21, 26) One study reported initial 
hospitalisation for six patients; three during washout, two during placebo and one during 
synbiotic periods. (9) Two studies each had one patient die of a myocardial infarct during 
the study period, both of which were deemed unrelated to the study intervention. (21, 26) 
None of the included studies reported on progression to ESKD as an outcome measure. 
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Patient-centred outcomes 
Faecal characteristics were reported in four of the included studies. (7, 18, 20, 23) Two 
studies utilised the Bristol Stool Scale to measure stool consistency, with both reporting no 
effect after prebiotic and synbiotic supplementation. (7, 20) Stool frequency was reported in 
two studies with no effect after synbiotic supplementation (P=0.92)(7) or prebiotic 
supplementation (P=0.48) (18). Younes et al (23) noted an increase in stool weight after 
prebiotic supplementation (P<0.05).  
 
Gastrointestinal tolerance was investigated using a variety of measures: Gastrointestinal 
Symptom Rating Scale (GSRS) (9, 25), other patient-reported questionnaires (7, 20, 28) and 
through patient interviews (8, 18, 22, 27). No significant change in GSRS scores were noted 
after synbiotic supplementation (P=0.168 (9) and P=0.72 (25)). An increase in flatulence was 
reported in two prebiotic interventions (7, 18), while improvements in bloating (P≤0.05) and 
constipation (P≤0.05) were noted after synbiotic supplementation. (28) 
 
Colonic transit time was not reported in any of the included studies.  
 
A variety of measures were utilised to assess adherence to treatment, with pill count the 
most common. (8, 9, 24, 26-28) Overall adherence to nutrition supplementation was high, 
ranging from 82% to 97%. (7, 9, 24, 26, 27) 
 
Health related quality of life (QoL) was assessed using a range of tools (SF-36 (9, 26), Kidney 
Disease Quality of Life Short Form-36 (KDQoL-36) (8) and utilising a 10-point scale (21, 22)). 
 13 
No significant change to quality of life was found in three studies (8, 9, 26), while one study 
found 85% (P>0.05) of participants had a perceived higher quality of life during the 
intervention period (22). 
 
Discussion  
This systematic review assessed the effectiveness of pre-, pro- and/or synbiotic 
supplementation in adults with CKD. In mostly low certainty evidence, pooled results 
indicated that nutrition supplementation may have had little or no effect on eGFR, serum 
creatinine, serum urea, serum IS, serum PCS, blood glucose levels, weight, total cholesterol, 
LDL cholesterol, HDL cholesterol or triglyceride levels. Prebiotic supplementation may have 
slightly reduced serum urea concentrations (-2.23mmol/L P=0.006), although there was no 
appreciable effect with probiotic or synbiotic supplementation. Additionally, there may have 
been a positive benefit with all three types of nutrition supplementation (pre-, pro- and 
synbiotics) on serum urea concentrations (-2.12mmol/L P=0.02) in non-dialysis dependent 
CKD, however not to those who were dialysis dependent.  
 
The reduction in serum urea with prebiotic supplementation is supported by the results of 
an earlier systematic review which found that dietary fibre intake was associated with 
significant reductions in serum urea (MD −1.76mmol/L (95% CI, −3.00, −0.51), P<0.01) in 
CKD. (31) Reducing serum urea concentrations in CKD may be of importance as the diffusion 
of urea into the gut lumen favours the growth of intestinal bacteria that express urease as 
well as those that produce uraemic toxins. Increased urease expression promotes the 
degradation of urea leading to the erosion of the epithelial barrier, thereby promoting 
systemic inflammation. (32, 33)   The low certainty of effect of pre-, pro- and synbiotic 
 14 
supplementation on the uraemic toxins, IS and PCS, reflects the conflicting findings found in 
individual studies with increases, decreases and neutral effects reported in the literature. 
(10-12) Study design was likely an important limiting factor underpinning the disparate 
findings, given the short intervention durations (4 - 12 weeks), small participant numbers 
(31-40) and variable product formulations in these studies.   
 
Microbiota composition was investigated in two studies, with synbiotic supplementation 
leading to higher abundances of Bifidobacterium (9, 25) and Lachnospiraceae  (9) and a 
decrease in Ruminococcaceae (9). Although the significant change in microbiota 
composition is encouraging, it is important to note that product formulation and dosage 
differed between the two studies and only one study considered the potential modifying 
effects of participants’ baseline microbiota profiles (9). Moreover, both studies utilised 
faecal samples as a surrogate for gut microbiota composition, even though this may not 
have accurately reflected the colonic mucosal microbiota. (34)  
 
Pre- pro- and synbiotic supplementation appeared to be well-tolerated with few 
gastrointestinal side-effects. In conjunction with a high rate of patient adherence, few 
adverse events and no decrease in health-related quality of life, this preliminary, low 
certainty evidence suggested that pre-, pro- and synbiotic supplementation may be safe, 
well-tolerated and acceptable forms of supplementation within the CKD population. 
 
To our knowledge, this is the first systematic review investigating the effects of pre-, pro- 
and/or synbiotic supplementation on clinical and patient-centred outcomes in the CKD 
population. The strengths of this study included its robust design and comprehensive search 
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strategy. However, it is acknowledged that this study had some limitations. Only a limited 
number of studies reported the primary outcome of kidney function and damage. The wide 
variability in product formulations further limited comparisons between interventions and 
measured outcomes. Moreover, some studies possibly provided inadequate amounts of 
product and/or an insufficient duration of treatment (2 to 24 weeks) to elicit a therapeutic 
response. (35) The prebiotic studies evaluated used dosages ranging from 10 - 50g/day, 
while the synbiotic studies used significantly lower dosages of prebiotic (2.3 – 15g/day). A 
prebiotic dose of >5g/day has previously been shown to influence microbiota diversity, 
while a threshold dose of 15-20g/day may be required to reduce uraemic toxin 
concentrations. (36) The included probiotic studies contained an array of strains and 
dosages. In other chronic diseases, the therapeutic response to probiotics has been strain 
specific (37), indicating that a specific mix of bacterial genera and dosages may be required 
for the CKD population. The responses to pre-, pro- and synbiotic supplementation may also 
have been influenced by a number of within-study factors, such as antibiotic use (38), wash-
out periods (39) and dietary intake (40, 41). Antibiotic use throughout the intervention 
period was only documented in one study. (9) A number of studies either did not describe 
or did not include a wash-out period (18, 21-23), potentially confounding the results. Few 
studies included in this review controlled for potential dietary confounders. Finally, when 
applying the GRADE assessment, most studies were rated as “moderate” to “very low” 
quality thereby reducing confidence that the observed effect size was representative of the 
true effect.  
 
Practical Applications 
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At this time, there is limited evidence to support the use of pre-, pro- and synbiotic 
supplementation in CKD. However, the observed reduction in serum urea in non-dialysis 
dependent CKD patients is promising. Due to the small number of available studies it is 
premature to conclude whether one type of nutrition supplementation is superior to 
another at this time. Further well-designed interventions are required to establish the most 
appropriate supplementation formulation and its influence on patient-level outcomes. 
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Table 1: Characteristics of included prebiotic, probiotic and synbiotic interventions in CKD 
Author, year Study Design Participants Intervention Time Primary Outcome Measure 
Potential Confounders 
Assessed 
Diet 
Washout 
Period Compliance 
Bliss, 
1996 
Single-blind, 
crossover RCT 
n=16 (63% male) 
Non-dialysis 
Prebiotic: 50g gum arabic 1 wk Stool weight, bacterial mass, faecal N, urinary N   No No No 
Younes, 
2006 
Crossover 
RCT 
n=9 (67% male) 
Non-dialysis 
Prebiotic: 40g Fermentable CHO 2 wks Faecal N and stool weight, urinary N 
 
No Yes Yes 
Sirich, 
2014 
Single-blind 
RCT 
n=40 (60% male) 
Haemodialysis 
Prebiotic: 30g Hi-maize 260 6 wks Free and total plasma IS and PCS No NA Yes 
Xie, 
2015 
RCT n=124 (55% male) 
Haemodialysis 
Prebiotic: 10g or 20g soluble dietary fibre  6 wks Lipid profile, oxidative and inflammatory status Yes NA No 
Poesen, 
2016 
Double-blind 
Crossover 
RCT 
n=40 (70% male) 
CKD Stage: 3b, 4 
Prebiotic: 20g arabinoxylan oligosaccharides 
(AXOS)  
4 wks TMAO, PCS, PCG, IS, PAG, urea 
 
Yes Yes Yes 
Ranganathan, 
2009 (pilot) 
Double-blind, 
crossover RCT 
n=13 (69% male) 
CKD Stage: 3, 4 
Probiotic: 9x1010 CFU/day (Kibow Biotics®: 
S.thermophilus KB19, L.acidophilus KB27, and 
B.longum KB31) 
3 mths BUN, uric acid, serum creatinine or CRP 
Gut microbiota 
No No No 
Ranganathan, 
2010 (pilot) 
Double-blind, 
Crossover 
RCT 
n=46 (67% male) 
CKD Stage: 3, 4 
Probiotic: 9x1010 CFU/day (Kibow Biotics) 3 mths BUN, serum creatinine, uric acid 
QoL 
No No No 
Natarajan, 
2014 
Double-blind, 
Crossover 
RCT 
n=22 (27% male) 
Haemodialysis 
Probiotic: 18x1010 CFU/day (Renadyl®: 
S.thermophilus KB19, L.acidophilus KB27, and 
B.longum KB31) 
2 mths Indoxyl glucuronide, IS, PCS, IAA, hippuric acid 
Quality of life 
No Yes Yes 
Wang,  
2015 
Double-blind, 
RCT 
n=39 (46% male) 
Peritoneal Dialysis 
Probiotic: 4x109 CFU/day (B.bifidum A218, 
B.catenulatum A302, B.longum A101, 
L.platarum A87) 
6 mths Endotoxin No NA Yes 
Soleimani, 
2016 
Double-blind, 
RCT 
n=60 (67% male) 
Diabetic 
Haemodialysis 
Probiotic: 6 x 109 CFU/day (L.acidophilus, 
L.casei, and B.bifidum) 
3 mths Glucose homeostasis Yes NA Yes 
Borges,  
2016 
Double-blind, 
RCT 
n=33 (64% male) 
Haemodialysis 
Probiotic: 90 x 109 CFU/day (S. thermophilus, 
L.acidophilus, B.longum) 
3 mths Serum urea, CRP, IL-6, IS, PCS, IAA  
faecal bacterial profile 
No NA Yes 
Cruz-Mora, 
2014 
Double-blind, 
RCT 
n=18 (83% male) 
Haemodialysis 
Synbiotic (Nutrihealth®):  
- Prebiotic: 2.3g/day (Inulin) 
- Probiotic: 2x1012 CFU/day (L. acidophilus & B. 
bifidum) 
2 mths Gut microbiota No NA No 
Guida, 
2014 
Double-blind, 
RCT 
n=30 (87% male) 
CKD Stage: 3, 4 
Synbiotic (Probinul neutro®) 
- Prebiotic: 6.6g/day (inulin) 
- Probiotic: 5,7x1010 CFU/day (L.plantarum, 
L.casei subsp. Rhamnosus, L.gasseri, B.infantis,  
1 mth Plasma p-cresol  Yes NA No 
Author, year Study Design Participants Intervention Time Primary Outcome Measure 
Potential Confounders 
Assessed 
Diet 
Washout 
Period Compliance 
B.longum, L.acidophilus, L.salivarius, 
L.sporogenes, S.thermophilus) 
Viramontes-
Horner, 2015 
Double-blind, 
RCT 
n=35 (91% male) 
Haemodialysis 
Synbiotic (Nutrihealth®):  
- Prebiotic: 2.3g/day (inulin) 
- Probiotic: 11x106 CFU/day (L.acidophilus 
NCFM and B. lactis Bi-07) 
- plus: omega-3 and vitamins 
2 
moths 
GI symptoms  
 
Yes NA No 
Dehghani, 
2016 
Double-blind, 
RCT 
n=66 (76% male) 
CKD Stage: 3, 4 
Synbiotic (Familact®) 
- Prebiotic (FOS) 
- Probiotic: (L. casei, L. acidophilus, L. 
bulgarigus, L.rhamnosus, B. breve, B. longum, 
S. thermophilus) 
6 wks BUN, serum creatinine, uric acid, CrCl, eGFR No NA No 
Rossi, 
2016 
Double-blind, 
Crossover 
RCT 
 n=21 (62%) 
CKD Stage: 4, 5 
non-dialysed 
Synbiotic: 
- Prebiotic: 15g/day (Inulin, FOS & GOS) 
- Probiotic: 9 x 1010 CFU/day (9 strains from 
Lactobacillus, Bifidobacteria, and 
Streptococcus genera) 
 6 wks Serum IS Yes Yes Yes 
 
BUN: blood urea nitrogen; CFU: Colony forming unit; CHO: carbohydrate; CRP: c-reactive protein; FOS: fructooligosaccharide; GFR: glomerular filtration rate; GI: gastrointestinal symptoms; GOS: 
galactooligosaccharide; HDL-C: high density lipoprotein cholesterol; IAA: Indole 3-acetic acid; IL: interleukin; IS: indoxyl sulfate; LDL-C: low density lipoprotein cholesterol; N: nitrogen NCFM: North Carolina Food 
Microbiology; PCS: p-cresyl sulfate; PAG: phenylacetylglutamine; PCG: p-cresyl glucuronide; TC: total cholesterol; TG: triglycerides; TMAO: trimethylamine N-oxide; TNF-α: tumour necrosis factor α  
 
 
 
  
Table 2: Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment of pre- pro- and synbiotic 
supplementation compared to placebo in patients with chronic kidney disease 
 
 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study 
design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
  Relative 
(95% CI) 
Absolute 
(95% CI) 
Urea (follow up: range 4 weeks to 24 weeks; assessed with: mmol/L) 
9  randomised 
trials  
serious a,b,c,d not serious  not serious  serious e none  203  200  -  MD 0.3 
lower 
(2.2 lower 
to 1.61 
higher)  
⨁⨁◯◯ 
LOW  
NOT IMPORTANT  
p-cresyl sulphate (follow up: range 4 weeks to 24 weeks; assessed with: mg/dl) 
4  randomised 
trials  
serious d not serious  not serious  serious e none  97  98  -  MD 0.13 
lower 
(0.41 
lower to 
0.15 
higher)  
⨁⨁◯◯ 
LOW  
NOT IMPORTANT  
Indoxyl Sulphate (follow up: range 4 weeks to 24 weeks; assessed with: mg/dl) 
4  randomised 
trials  
serious d not serious  not serious  serious f none  97  98  -  MD 0.02 
lower 
(0.09 
lower to 
0.05 
higher)  
⨁⨁◯◯ 
LOW  
NOT IMPORTANT  
eGFR (follow up: range 4 weeks to 6 weeks; assessed with: mL/min/1.73m2) 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study 
design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
  Relative 
(95% CI) 
Absolute 
(95% CI) 
3  randomised 
trials  
not serious  not serious  not serious  serious e none  92  96  -  MD 0.34 
higher 
(2.2 lower 
to 2.89 
higher)  
  
⨁⨁⨁◯ 
MODERATE  
NOT IMPORTANT  
Weight (follow up: range 4 weeks to 24 weeks; assessed with: kg) 
7  randomised 
trials  
serious a,b,c,g not serious  not serious  serious e none  226  233  -  MD 0.4 
higher 
(0.95 
lower to 
1.74 
higher)  
⨁⨁◯◯ 
LOW  
NOT IMPORTANT  
Blood Glucose (follow up: range 4 weeks to 12 weeks; assessed with: mg/dl) 
2  randomised 
trials  
not serious  serious h not serious  serious e publication bias 
strongly suspected i 
70  70  -  MD 0.33 
lower 
(7.17 
lower to 
6.5 higher)  
⨁◯◯◯ 
VERY LOW  
NOT IMPORTANT  
Triglycerides (follow up: range 6 weeks to 12 weeks; assessed with: mg/dl) 
3  randomised 
trials  
serious a,b,c,g not serious  not serious  serious e publication bias 
strongly suspected i 
130  133  -  MD 1.57 
lower 
(22.56 
lower to 
19.42 
higher)  
⨁◯◯◯ 
VERY LOW  
NOT IMPORTANT  
Cholesterol (follow up: range 6 weeks to 12 weeks; assessed with: mg/dl) 
Certainty assessment № of patients Effect 
Certainty Importance № of 
studies 
Study 
design Risk of bias Inconsistency Indirectness Imprecision Other considerations 
  Relative 
(95% CI) 
Absolute 
(95% CI) 
3  randomised 
trials  
serious a,b,c,g serious h not serious  serious e none  130  133  -  MD 4.88 
lower 
(14.43 
lower to 
4.68 
higher)  
 
 
 
 
 
  
⨁◯◯◯ 
VERY LOW  
NOT IMPORTANT  
LDL Cholesterol (follow up: range 6 weeks to 12 weeks; assessed with: mg/dl) 
3  randomised 
trials  
serious a,b,c,g serious h not serious  serious e none  130  133  -  MD 11.76 
lower 
(15.15 
lower to 
8.36 
lower)  
⨁◯◯◯ 
VERY LOW  
NOT IMPORTANT  
CI: Confidence interval; MD: Mean difference a. Insufficient information about sequence generation b. Insufficient information about allocation concealment c. Selective reporting likely d. A 
number of included studies did not control for dietary changes nor assess participants dietary intake e. Small participant numbers and wide CI suggests both benefit and no benefit f. Small 
participant numbers g. Blinding was not adequate h. Significant heterogeneity I2>50% i. Publication bias suspected  
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Figure 1: Study selection for pre- pro- and synbiotic literature review in CKD 
Figure 2: Effects of pre- pro- and synbiotic supplementation on serum urea (mmol/L) in 
patients with CKD.  
Figure 3: Effects of pre- pro- and synbiotic supplementation on serum urea (mmol/L), by CKD 
stage.  
Figure 4: Risk of bias summary across the included studies. Unclear risk of bias: "?", Low risk 
of bias: "+", High risk of bias: "-" 
 
 
 
Figures 
 
 Figure 1: Flow chart describing pre- pro- and synbiotic study selection  
 
 
  
  
 
Figure 2: Effects of pre- pro- and synbiotic supplementation on serum urea (mmol/L) in 
patients with CKD. The means and SDs of changes from baseline are reported for trials. Effects 
of trials are presented as weights (percentages) and mean differences (95%CIs). IV, inverse 
variance. 
 
  
 Figure 3: Effects of pre- pro- and synbiotic supplementation on serum urea (mmol/L), by CKD 
stage. The means and SDs of changes from baseline are reported for trials. Effects of trials are 
presented as weights (percentages) and mean differences (95%CIs). IV, inverse variance. 
 
 
 
  
  
 
Figure 4: Risk of bias summary across the included studies. Unclear risk of bias: "?", Low risk 
of bias: "+", High risk of bias: "-" 
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Supplementary Figure 1: Effects of pre-, pro- and synbiotic therapy on eGFR(mL/min/1.73m2) 
in the CKD population.  
Supplementary Figure 2: Effects of pre-, pro- and synbiotic therapy on serum urea 
concentrations (mmol/L) in the CKD population.  
Supplementary Figure 3: Effects of pre-, pro- and synbiotic therapy on serum IS (mg/dL) in the 
CKD population.  
Supplementary Figure 4: Effects of pre-, pro- and synbiotic therapy on serum PCS (mg/dL) in 
the CKD population.  
Supplementary Figure 5: Effects of pre-, pro- and synbiotic therapy on BGL (mg/dL) in the 
CKD population. 
Supplementary Figure 6: Effects of pre-, pro- and synbiotic therapy on weight (kg) in the CKD 
population. 
Supplementary Figure 7: Effects of pre-, pro- and synbiotic therapy on total cholesterol levels 
(mg/dL) in the CKD population. 
Supplementary Figure 8: Effects of pre-, pro- and synbiotic therapy on LDL cholesterol levels 
(mg/dL) in the CKD population. 
Supplementary Figure 9: Effects of pre-, pro- and synbiotic therapy on triglyceride levels 
(mg/dL) in the CKD population. 
 
 
  
Supplementary Figure 1: Effects of pre-, pro- and synbiotic therapy on eGFR(mL/min/1.73m2) 
in the CKD population. The means and SDs of changes from baseline are reported for trials. 
Effects of trials are presented as weights (percentages) and mean differences (95%CIs). IV, 
inverse variance. 
 
 
  
Supplementary Figure 2: Effects of pre-, pro- and synbiotic therapy on serum urea 
concentrations (mmol/L) in the CKD population. The means and SDs of changes from 
baseline are reported for trials. Effects of trials are presented as weights (percentages) and 
mean differences (95%CIs). IV, inverse variance. 
 
 
 Supplementary Figure 3: Effects of pre-, pro- and synbiotic therapy on serum IS (mg/dL) in 
the CKD population. The means and SDs of changes from baseline are reported for trials. 
Effects of trials are presented as weights (percentages) and mean differences (95%CIs). IV, 
inverse variance. 
 
Supplementary Figure 4: Effects of pre-, pro- and synbiotic therapy on serum PCS (mg/dL) in 
the CKD population. The means and SDs of changes from baseline are reported for trials. 
Effects of trials are presented as weights (percentages) and mean differences (95%CIs). IV, 
inverse variance. 
 
 
 
  
Supplementary Figure 5: Effects of pre-, pro- and synbiotic therapy on BGL (mg/dL) in the 
CKD population. The means and SDs of changes from baseline are reported for trials. Effects 
of trials are presented as weights (percentages) and mean differences (95%CIs). IV, inverse 
variance. 
 
 
  
Supplementary Figure 6: Effects of pre-, pro- and synbiotic therapy on weight (kg) in the CKD 
population. The means and SDs of changes from baseline are reported for trials. Effects of 
trials are presented as weights (percentages) and mean differences (95%CIs). IV, inverse 
variance. 
 
 
 
 
Supplementary Figure 7: Effects of pre-, pro- and synbiotic therapy on total cholesterol levels 
(mg/dL) in the CKD population. The means and SDs of changes from baseline are reported 
for trials. Effects of trials are presented as weights (percentages) and mean differences 
(95%CIs). IV, inverse variance. 
 
 
  
Supplementary Figure 8: Effects of pre-, pro- and synbiotic therapy on LDL cholesterol levels 
(mg/dL) in the CKD population. The means and SDs of changes from baseline are reported 
for trials. Effects of trials are presented as weights (percentages) and mean differences 
(95%CIs). IV, inverse variance. 
 
 
Supplementary Figure 9: Effects of pre-, pro- and synbiotic therapy on triglyceride levels 
(mg/dL) in the CKD population. The means and SDs of changes from baseline are reported 
for trials. Effects of trials are presented as weights (percentages) and mean differences 
(95%CIs). IV, inverse variance. 
 
